CMP: $34

Bristol-Myers Squibb Company is a global biopharmaceutical company. The Company develops, licenses, manufactures, markets, and sells pharmaceutical and nutritional products. Bristol-Myers Squibb products and experimental therapies address cancer, heart disease, HIV/AIDS, diabetes, rheumatoid arthritis, hepatitis, organ transplant rejection, and psychiatric disorders.

Bristol-Myers is a $57 Billion market cap company trading at a P/E of 31. Revenues have risen from $18.80 Billion to $21.24 Billion in the last 2 years. Profits have risen from $3.20 Billion to $3.71 Billion in the last 2 years. With a balanced long term debt, it looks a good buy for long term.